PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8263640-11 1994 C-reactive protein was significantly reduced on postoperative days 1, 2, and 3 (P < .05) in both dexamethasone groups. Dexamethasone 100-113 C-reactive protein Homo sapiens 0-18 8263640-13 1994 Measurement of C-reactive protein seems to be the most sensitive method for comparing the effect of dexamethasone on postoperative inflammation. Dexamethasone 100-113 C-reactive protein Homo sapiens 15-33 8343015-8 1993 The blood CRP level of the dexamethasone plus antibiotics group decreased significantly within 48 hours. Dexamethasone 27-40 C-reactive protein Homo sapiens 10-13 8343015-11 1993 The relatively frequent transient recurrences of fever and increased CRP when dexamethasone was interrupted suggest that the dose and/or duration of dexamethasone treatment should be modified. Dexamethasone 78-91 C-reactive protein Homo sapiens 69-72 8343015-11 1993 The relatively frequent transient recurrences of fever and increased CRP when dexamethasone was interrupted suggest that the dose and/or duration of dexamethasone treatment should be modified. Dexamethasone 149-162 C-reactive protein Homo sapiens 69-72 1667244-5 1991 Incubation of HepG2 cells simultaneously with IL-6 and dexamethasone increases the magnitude of CRP release significantly above that seen with IL-6 alone. Dexamethasone 55-68 C-reactive protein Homo sapiens 96-99 1667244-6 1991 After preincubation with dexamethasone, the kinetics of CRP release, induced by IL-6, are increased and approach that observed in the case of alpha 1-acid glycoprotein (alpha 1-AGP) without dexamethasone pretreatment. Dexamethasone 25-38 C-reactive protein Homo sapiens 56-59 1667244-6 1991 After preincubation with dexamethasone, the kinetics of CRP release, induced by IL-6, are increased and approach that observed in the case of alpha 1-acid glycoprotein (alpha 1-AGP) without dexamethasone pretreatment. Dexamethasone 190-203 C-reactive protein Homo sapiens 56-59 34273116-9 2021 The "no dexamethasone" cohort 25-OH-D deplete subgroup recorded significantly higher peak D-Dimer levels (1874ugFEU/L vs 1233ugFEU/L) (p value = 0.0309), CRP (177 vs 107.5) (p=0.0055) and ventilatory support requirement (25.5% vs 6.67%) (p value = 0.007) compared to the replete subgroup. Dexamethasone 4-17 C-reactive protein Homo sapiens 150-153 1651357-12 1991 These data indicate that IL-6, IL-1 alpha, TNF-alpha, and dexamethasone in various combinations are all capable of influencing synthesis of SAA in Hep 3B cells, whereas only IL-6, IL-1 alpha, and dexamethasone can influence CRP synthesis. Dexamethasone 58-71 C-reactive protein Homo sapiens 224-227 2242421-5 1990 The concurrent administration of dexamethasone also prevented the IL-2-induced increase in serum levels of C-reactive protein, a hepatic acute phase reactant whose synthesis is regulated by proinflammatory cytokines such as TNF. Dexamethasone 33-46 C-reactive protein Homo sapiens 107-125 1651357-1 1991 We have previously shown that induction of synthesis of the two major human acute phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP), can be accomplished in the human hepatoma cell line Hep 3B, in the presence of dexamethasone, either by conditioned medium from LPS-stimulated monocytes or by the combination of IL-6 and IL-1. Dexamethasone 229-242 C-reactive protein Homo sapiens 124-142 1651357-1 1991 We have previously shown that induction of synthesis of the two major human acute phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP), can be accomplished in the human hepatoma cell line Hep 3B, in the presence of dexamethasone, either by conditioned medium from LPS-stimulated monocytes or by the combination of IL-6 and IL-1. Dexamethasone 229-242 C-reactive protein Homo sapiens 144-147 34214123-9 2021 However, dexamethasone was associated marginally with increased SpO2/FiO2 and significantly with decreases in C-reactive protein and radiologic score after adjusting for baseline imbalances. Dexamethasone 9-22 C-reactive protein Homo sapiens 110-128 34455200-9 2021 Dexamethasone (8 mg) resulted in increased levels of LTB4 (P = 0.012) and 20-HETE (P = 0.009) and reduced hs-CRP levels (P<0.001). Dexamethasone 0-13 C-reactive protein Homo sapiens 109-112 34455200-11 2021 CONCLUSION: Antiemetic doses of dexamethasone given during surgery increased plasma LTB4 and 20-HETE at a time when hs-CRP was significantly reduced. Dexamethasone 32-45 C-reactive protein Homo sapiens 119-122 34353339-0 2021 Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Dexamethasone 0-13 C-reactive protein Homo sapiens 74-92 34353339-3 2021 We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone with or without tocilizumab, and assessed the value of these biomarkers to detect secondary bacterial infections. Dexamethasone 86-99 C-reactive protein Homo sapiens 24-27 34353339-7 2021 RESULTS: Following cessation of dexamethasone, there was a rebound in PCT and CRP levels, most pronounced in the D+T- group. Dexamethasone 32-45 C-reactive protein Homo sapiens 78-81 34353339-12 2021 CONCLUSIONS: Cessation of dexamethasone in critically ill COVID-19 patients results in a rebound increase in PCT and CRP levels unrelated to the occurrence of secondary bacterial infections. Dexamethasone 26-39 C-reactive protein Homo sapiens 117-120 34353339-13 2021 Furthermore, immunomodulatory treatment with dexamethasone and tocilizumab considerably reduces the value of PCT and CRP for detection of secondary infections in COVID-19 patients. Dexamethasone 45-58 C-reactive protein Homo sapiens 117-120 34235458-4 2021 His C-reactive protein levels started to decrease with tocilizumab and dexamethasone treatments. Dexamethasone 71-84 C-reactive protein Homo sapiens 4-22 35584822-7 2022 After dexamethasone became standard treatment for COVID-19 pneumonia, mean maximal CRP decreased by 17 mg/dL (95% CI -22 to -11). Dexamethasone 6-19 C-reactive protein Homo sapiens 83-86 2454996-3 1988 Conditioned medium (CM) prepared from human blood monocytes activated with LPS in the presence of dexamethasone led to substantial induction of serum amyloid A (SAA) and C-reactive protein (CRP) synthesis whereas the defined cytokines IL-1 beta, TNF alpha, and medium from a human keratinocyte cell line (COLO-16), containing hepatocyte-stimulating factor activity, failed to induce these two major APP. Dexamethasone 98-111 C-reactive protein Homo sapiens 170-188 35347166-0 2022 C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Dexamethasone 53-66 C-reactive protein Homo sapiens 0-18 35347166-11 2022 The crude analysis showed a mortality reduction in patients receiving dexamethasone when CRP was > 13.75 mg/dL and > 3.5 mg/dL for those receiving tocilizumab. Dexamethasone 70-83 C-reactive protein Homo sapiens 89-92 35347166-12 2022 Multivariate analysis identified the interaction of CRP > 13.75 mg/dL with dexamethasone (OR 0.57; CI 95% 0.37-0.89, P = 0014) and CRP > 3.5 mg/dL with tocilizumab (0.65; CI95%:0.44-0.95, P = 0.029) as independent predictors of mortality. Dexamethasone 75-88 C-reactive protein Homo sapiens 52-55 35347166-13 2022 Our results suggest that dexamethasone and tocilizumab are associated with a reduction in mortality when prescribed to patients with a certain inflammatory activity assessed by C-reactive protein. Dexamethasone 25-38 C-reactive protein Homo sapiens 177-195 2454996-3 1988 Conditioned medium (CM) prepared from human blood monocytes activated with LPS in the presence of dexamethasone led to substantial induction of serum amyloid A (SAA) and C-reactive protein (CRP) synthesis whereas the defined cytokines IL-1 beta, TNF alpha, and medium from a human keratinocyte cell line (COLO-16), containing hepatocyte-stimulating factor activity, failed to induce these two major APP. Dexamethasone 98-111 C-reactive protein Homo sapiens 190-193 29335791-1 2018 PURPOSE: To clarify pre- and postoperative C-reactive protein (CRP) levels in patients with facial fractures and to investigate the influence of perioperatively administered dexamethasone on postoperative CRP levels. Dexamethasone 174-187 C-reactive protein Homo sapiens 205-208 33259720-7 2021 There were significant differences in inflammatory markers between the two groups: interleukin-6 (p = 0.0001), procalcitonin (p = 0.0001), and C-reactive protein (p = 0.0001) were lower in the dexamethasone group. Dexamethasone 193-206 C-reactive protein Homo sapiens 143-161 31441836-9 2019 CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA. Dexamethasone 49-53 C-reactive protein Homo sapiens 103-106 30268443-3 2019 Here, we observed the effects of peri-operative dexamethasone on the APR following TKA by trending C-reactive protein (CRP, mg/L) and fibrinogen (mg/dL). Dexamethasone 48-61 C-reactive protein Homo sapiens 99-117 30268443-3 2019 Here, we observed the effects of peri-operative dexamethasone on the APR following TKA by trending C-reactive protein (CRP, mg/L) and fibrinogen (mg/dL). Dexamethasone 48-61 C-reactive protein Homo sapiens 119-122 30268443-8 2019 RESULTS: Compared to the non-steroid group, patients receiving dexamethasone yielded a significantly decreased CRP on POD0 (5.5 vs 8.3), POD1 (11.8 vs 22.0), and POD2 (85.5 vs 148.9). Dexamethasone 63-76 C-reactive protein Homo sapiens 111-114 32570995-6 2020 RESULTS: CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge. Dexamethasone 67-80 C-reactive protein Homo sapiens 9-12 32347005-6 2020 RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively. Dexamethasone 57-60 C-reactive protein Homo sapiens 13-16 31587982-10 2020 The DEX group also had lower rates of nausea and vomiting: 29/50 (58%) vs 42/50 (84%) (P = .008) and lower mean C-reactive protein level: 89 vs 167, Delta = -78 mg/L (95% CI, -100 to -58 mg/L, P < .0001). Dexamethasone 4-7 C-reactive protein Homo sapiens 112-130 29335791-6 2018 However, postoperative CRP rise was significantly impeded by dexamethasone (p < 0.001), regardless of gender, age, treatment delay, site of fracture, surgical approach, and duration of surgery. Dexamethasone 61-74 C-reactive protein Homo sapiens 23-26 29335791-7 2018 CRP rise halved on the 1st postoperative day when dexamethasone was used. Dexamethasone 50-63 C-reactive protein Homo sapiens 0-3 29335791-8 2018 In addition, dexamethasone resulted in a CRP decrease on the 2nd postoperative day, whereas the CRP rise continued in the control group. Dexamethasone 13-26 C-reactive protein Homo sapiens 41-44 29335791-9 2018 CONCLUSIONS: CRP rise is a normal body response after facial fracture and surgery that can be markedly reduced with dexamethasone. Dexamethasone 116-129 C-reactive protein Homo sapiens 13-16 29335791-10 2018 CRP changes should be considered with caution if perioperative dexamethasone is used. Dexamethasone 63-76 C-reactive protein Homo sapiens 0-3 28647788-11 2018 CONCLUSIONS: The administration of two low-dose peri-operative dexamethasone can effectively reduce the post-operative level of CRP and IL-6, provide additional pain and nausea control, ameliorate post-operative fatigue, enhance mobility, and shorten post-operative LOS following THA, without increasing the risk of infection and gastrointestinal hemorrhage. Dexamethasone 63-76 C-reactive protein Homo sapiens 128-131 26667403-10 2016 CRP, IL-6, and cortisol were significantly lower in the dexamethasone group compared with the control group during the 24 hours after UAE. Dexamethasone 56-69 C-reactive protein Homo sapiens 0-3 28985195-10 2017 RESULTS: Compared to the placebo group, the dexamethasone group showed statistically significant reductions in the incidence of POCD (relative risk, 0.43; 95% confidence interval, 0.21 to 0.89; P = 0.02), the incidence of systemic inflammatory response syndrome (30.0 versus 58.0%, P < 0.001) and postoperative C-reactive protein levels (P < 0.001). Dexamethasone 44-57 C-reactive protein Homo sapiens 314-332 28251379-5 2017 RESULTS: In the propensity score-matched cohort, preoperative dexamethasone was associated with fewer patients exceeding the established CRP threshold of 150 mg/L on POD 3 (odds ratio [OR] 0.42, 95% confidence interval [CI] 0.26-0.70, p < 0.001) and fewer postoperative complications (OR 0.53, 95% CI 0.33-0.86, p = 0.009). Dexamethasone 62-75 C-reactive protein Homo sapiens 137-140 28487744-7 2017 Considering this, his confusion and his neutrophilia and high C-reactive protein levels, empirical antibiotics with dexamethasone were started and the patient responded to that. Dexamethasone 116-129 C-reactive protein Homo sapiens 62-80 20027097-11 2009 The dexamethasone group showed significantly less elevation of C-reactive protein levels at 24 hours (7.17 microg/mL vs. 17.53 microg/mL; P=0.003) and 48 hours (10.65 microg/mL vs. 23.18 microg/mL; P=0.02) postoperatively. Dexamethasone 4-17 C-reactive protein Homo sapiens 63-81 23681030-16 2013 Dexamethasone use significantly reduced postoperative levels of C-reactive protein (P = .01) and interleukin 6 and interleukin 1beta (P = .02), fatigue (P = .01), and overall pain during the first 24 postoperative hours (P = .04), as well as the total analgesic (ketorolac tromethamine) requirement (P = .04). Dexamethasone 0-13 C-reactive protein Homo sapiens 64-82 20845101-11 2010 Dexamethasone significantly reduced postoperative levels of CRP (p = 0.01), IL-6 and IL-1 (p < 0.05), fatigue (p = 0.01) and overall pain during the first 24 postoperative hours (p < 0.05) and the total requirement of analgesic (ketorolac) (p < 0.05). Dexamethasone 0-13 C-reactive protein Homo sapiens 60-63 25277829-7 2014 Compared with the other groups, the dexamethasone group had significantly higher CRP levels before and after surgery, a significantly higher N/L ratio before surgery, a significantly lower rise in the N/L ratio after surgery, and a significantly lower HLA-DR expression at baseline, which remained stable after surgery. Dexamethasone 36-49 C-reactive protein Homo sapiens 81-84 25048483-6 2014 After completion of the initial IVIG, C-reactive protein levels in the combined IVIG plus dexamethasone group were significantly lower than those in the IVIG only group (2.7+-4.0 mg/dL vs. 4.6+-8.7 mg/dL, p=0.03). Dexamethasone 90-103 C-reactive protein Homo sapiens 38-56 15769980-11 2005 Dexamethasone decreased resting heart rate, high-sensitivity C-reactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. Dexamethasone 0-13 C-reactive protein Homo sapiens 61-79 18349202-10 2008 C-reactive protein levels at 48 h were markedly reduced by dexamethasone (52.4 mg/mL, 28.2-76.6 vs 194.2, 168.9-219.4; P < 0.0001). Dexamethasone 59-72 C-reactive protein Homo sapiens 0-18 17289483-10 2007 DEX significantly reduced at least 1 postoperative level of IL-6, IL-8, IL-10, CRP, and exhaled NO. Dexamethasone 0-3 C-reactive protein Homo sapiens 79-82 17016627-7 2006 Dexamethasone attenuated the effects of MIF upon CRP production but increased the MIF stimulated release of ACT. Dexamethasone 0-13 C-reactive protein Homo sapiens 49-52 10410263-9 1999 The decrease in ESR, CRP and the Thompson joint score was also significantly greater (all p < 0.05) for the high plasma dexamethasone group. Dexamethasone 123-136 C-reactive protein Homo sapiens 21-24 15695139-2 2005 Compared with controls, dexamethasone-eluting stents significantly reduced C-reactive protein peak levels 48 hours after the procedure; this effect persisted for 7 days and was particularly evident in patients with elevated (>/=3 mg/L) preprocedural C-reactive protein values. Dexamethasone 24-37 C-reactive protein Homo sapiens 75-93 15695139-2 2005 Compared with controls, dexamethasone-eluting stents significantly reduced C-reactive protein peak levels 48 hours after the procedure; this effect persisted for 7 days and was particularly evident in patients with elevated (>/=3 mg/L) preprocedural C-reactive protein values. Dexamethasone 24-37 C-reactive protein Homo sapiens 253-271 14963702-8 2004 Post-treatment C-reactive protein in the DEX group (median 0.9 mg/dl, range 0.0 to 24.7 mg/dl) was lower than that (1.2 mg/dl, range 0.2 to 19.5 mg/dl) in the CONTROL group ( P=0.033 by Mann-Whitney U test). Dexamethasone 41-44 C-reactive protein Homo sapiens 15-33 14578725-12 2003 Dexamethasone significantly reduced postoperative levels of CRP (P = 0.01), fatigue (P = 0.01), overall pain, and incisional pain during the first 24 postoperative hours (P < 0.05) and total requirements of opioids (P < 0.05). Dexamethasone 0-13 C-reactive protein Homo sapiens 60-63 12765886-6 2003 RESULTS: Dexamethasone decreased C-reactive protein concentration on the first postoperative day (P<0.05), but did not affect the release of vWf:Ag or S100B. Dexamethasone 9-22 C-reactive protein Homo sapiens 33-51 7523502-5 1994 CRP protein, identified by immunoprecipitation of a 25-kDa band with Abs to CRP, was induced in Hep3B cells by IL-1, IL-6, or dexamethasone. Dexamethasone 126-139 C-reactive protein Homo sapiens 0-3 9813941-2 1998 The effect of intravenous dexamethasone on the results of C-reactive protein, white blood cell count and erythrocyte sedimentation rate during the expectant management of premature rupture of membranes]. Dexamethasone 26-39 C-reactive protein Homo sapiens 58-76 9256019-4 1997 Effect of dexamethasone administration on SAA and CRP values was studied in 10 subjects who received a dexamethasone suppression test. Dexamethasone 10-23 C-reactive protein Homo sapiens 50-53 7523502-5 1994 CRP protein, identified by immunoprecipitation of a 25-kDa band with Abs to CRP, was induced in Hep3B cells by IL-1, IL-6, or dexamethasone. Dexamethasone 126-139 C-reactive protein Homo sapiens 76-79